Eupraxia's (EPRX) Blockbuster Opportunity Not Fully Priced In - Cantor Fitzgerald
Tweet Send to a Friend
Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $11.00 price target on Eupraxia Pharmaceuticals (NASDAQ: EPRX).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
